drugset

Drugs / CA-170

Follow last change May 2020 re-read 3 minutes ago

CA-170

Developed for: neoplastic disease or syndrome
Investigated by: Curis, Inc.

Trials 1

today NCT02812875 · Ph 1

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02812875	May 2016 → May 2020	neoplastic disease or syndrome	Curis, Inc.	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2017-09-11	Curis, Inc.	Results Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 curis.com ↗ Four immunotherapy treatment-naïve patients treated with CA-170 experienced shrinkage of their tumors.
2016-11-09	Curis, Inc.	Results Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170's Phase 1 Trial at the SITC 2016 Conference curis.com ↗ Further, evaluation of patient blood samples demonstrate that CA-170 appears to be biologically active in modulating the immune system, with a several-fold increase in percentage of circulating CD8+ T cells expressing activation markers within 24 hours of oral dosing.
2016-06-01	Curis, Inc.	Regulatory Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints curis.com ↗
2015-11-08	Curis, Inc.	Results Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC International Conference curis.com ↗

All press releases naming this drug 9 releases

Date	Issuer	Release
2020-02-06	Curis, Inc.	Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 curis.com ↗
2017-09-11	Curis, Inc.	Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 curis.com ↗
2017-08-31	Curis, Inc.	Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress curis.com ↗
2017-05-25	Curis, Inc.	Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting curis.com ↗
2016-11-09	Curis, Inc.	Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170's Phase 1 Trial at the SITC 2016 Conference curis.com ↗
2016-06-21	Curis, Inc.	Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints curis.com ↗
2016-06-01	Curis, Inc.	Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints curis.com ↗
2016-04-10	Curis, Inc.	Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting curis.com ↗
2015-11-08	Curis, Inc.	Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC International Conference curis.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CA-170	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02812875 ↗
Action	Inhibit	“Checkpoint Antagonist” NCT02812875 ↗
Modality	Small molecule	“small molecule” NCT02812875 ↗
Route	Oral	“Taken orally in a once or twice daily schedule.” NCT02812875 ↗